- Date 15 Apr 2021
Patent supports the unique potential of Biofidelity’s technology to deliver ultra-sensitive detection of guideline-recommended tumor markers.
Biofidelity Ltd, the cancer diagnostics company, today announced that it has been granted a key patent in the US protecting its underlying technology. The grant of US patent US20200354786 has confirmed the novelty and inventiveness of its technology, which is designed to break down barriers to better screening, monitoring and treatment of cancer through ultra-sensitive detection of the key tumor markers recommended in treatment guidelines.
It combines fast, easy-to-interpret results with affordability, enabling oncologists to make precise decisions earlier, monitor resistance and track disease recurrence. Biofidelity expects to launch its first product, Identi-Lung, for the detection of non-small cell lung cancer, later this year.